Zam-Zam
Senator
Good news for anyone not rooting for the virus:
The global search for a coronavirus vaccine appears to be taking flight, with a number of drug companies pressing ahead with clinical trials — including a late announcement from Pfizer (PFE) entering Phase 3 with one of its candidates developed with BioNTech (BNTX).
Progress on an effective COVID-19 inoculation comes as the virus continues to claim new victims worldwide, while the U.S. fights an uphill battle to contain a surge in confirmed cases. Vaccines remain a key to ending the severe restrictions on public life, which include public mask-wearing and social distancing — all of which have become flashpoints in U.S. political discourse.
Yet the headway on vaccines has made Anthony Fauci, the federal government’s top infectious disease expert, “cautiously optimistic” that a potential vaccine candidate could emerge by late fall, he said on Tuesday. In a recent Yahoo Finance interview, Fauci said the accelerated push was “worth it” despite the inherent risks.
On an earlings call Tuesday, Pfizer’s (PFE) CEO Albert Bourla said they company expects to have some sort of news and completed regulatory review by October 2020. The company had four potential candidates and has advanced one of those — a two-shot 30-microgram dose — into the final phase.
Moderna (MRNA) also announced its Phase 3 trial yesterday, which it is doing with significant funding and support from the federal government. Johnson & Johnson (JNJ) also announced entering phase 1 of its candidate Monday.
Pfizer executives told investors Tuesday they see the pandemic as a source of recurring revenue with the vaccine becoming a seasonal need, like the flu, and pricing adjusting accordingly. The current price of $19.50 is based on 100 million doses bought at $1.95 billion by the federal government, and is lower than the value the company believes the drug has for society, according to Bourla.
Pricing has been a point of concern for some patient advocacy groups, who believe companies should be providing the vaccine at no-profit costs.
Angela Hwang, global president of biopharmaceuticals at Pfizer, said on Tuesday the company would not offer other countries a lesser price than the U.S., except for poorer countries.
"No country in the developed world will receive (COVID-19 vaccine) doses at a lower price than the U..S." for similar volume commitments, Hwang added.
finance.yahoo.com
The global search for a coronavirus vaccine appears to be taking flight, with a number of drug companies pressing ahead with clinical trials — including a late announcement from Pfizer (PFE) entering Phase 3 with one of its candidates developed with BioNTech (BNTX).
Progress on an effective COVID-19 inoculation comes as the virus continues to claim new victims worldwide, while the U.S. fights an uphill battle to contain a surge in confirmed cases. Vaccines remain a key to ending the severe restrictions on public life, which include public mask-wearing and social distancing — all of which have become flashpoints in U.S. political discourse.
Yet the headway on vaccines has made Anthony Fauci, the federal government’s top infectious disease expert, “cautiously optimistic” that a potential vaccine candidate could emerge by late fall, he said on Tuesday. In a recent Yahoo Finance interview, Fauci said the accelerated push was “worth it” despite the inherent risks.
On an earlings call Tuesday, Pfizer’s (PFE) CEO Albert Bourla said they company expects to have some sort of news and completed regulatory review by October 2020. The company had four potential candidates and has advanced one of those — a two-shot 30-microgram dose — into the final phase.
Moderna (MRNA) also announced its Phase 3 trial yesterday, which it is doing with significant funding and support from the federal government. Johnson & Johnson (JNJ) also announced entering phase 1 of its candidate Monday.
Pfizer executives told investors Tuesday they see the pandemic as a source of recurring revenue with the vaccine becoming a seasonal need, like the flu, and pricing adjusting accordingly. The current price of $19.50 is based on 100 million doses bought at $1.95 billion by the federal government, and is lower than the value the company believes the drug has for society, according to Bourla.
Pricing has been a point of concern for some patient advocacy groups, who believe companies should be providing the vaccine at no-profit costs.
Angela Hwang, global president of biopharmaceuticals at Pfizer, said on Tuesday the company would not offer other countries a lesser price than the U.S., except for poorer countries.
"No country in the developed world will receive (COVID-19 vaccine) doses at a lower price than the U..S." for similar volume commitments, Hwang added.
Coronavirus update: Pfizer enters Phase 3 vaccine trial, Kodak tapped to produce drug ingredients
The global search for a coronavirus vaccine appears to be taking flight, with a number of drug companies making headway on a possible treatment.
finance.yahoo.com
